SHARE
 
Mark E. Burkard, MD, PhD close
CunDgBBc5DY

Mark E. Burkard, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Mark Burkard is an assistant professor of medicine in the Hematology-Oncology section of the UW School of Medicine and Public Health and is a member of the UW Health Breast Center. Dr. Burkard received his medical degree and PhD in chemistry from the University of Rochester. He subsequently trained in internal medicine at New York Hospital-Cornell University and in medical oncology at Memorial Sloan-Kettering Cancer Center. During his oncology fellowship, he studied cell cycle enzymes as novel targets for cancer therapy. He is board certified in Internal Medicine and Medical Oncology. As an oncologist, his clinical practice and research interest is in breast cancer and experimental therapeutics.

Specialties

Medical Oncology

Breast Cancer

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 266-6400 | (800) 323-8942 | Map
University Hospital
(608) 266-6400 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Memorial Sloan-Kettering Cancer Center, New York, NY
Medical School University of Rochester School of Medicine, Rochester, NY

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Burkard is interested in targeted therapy directed at protein kinases. His laboratory seeks to link therapies with their targets within cancer cells using genetic tools, and to identify patients whose cancers are most likely to benefit from particular drugs. These studies will be used to inform clinical development of novel agents. Dr. Burkard is part of the breast cancer disease oriented working group.


PubMed Articles
Denu RA Kaur G Sass MM Lakkaraju A Burkard ME Centrosome amplification in cancer disrupts autophagy and sensitizes to autophagy inhibition. Mol Cancer Res . 2019 Oct 11;
[PubMed ID: 31604847]
Lera RF Norman RX Dumont M Dennee A Martin-Koob J Fachinetti D Burkard ME Plk1 protects kinetochore-centromere architecture against microtubule pulling forces. EMBO Rep . 2019 Oct 4;20(10):e48711
[PubMed ID: 31468671]
Pasch CA Favreau PF Yueh AE Babiarz CP Gillette AA Sharick JT Karim MR Nickel KP DeZeeuw AK Sprackling CM Emmerich PB DeStefanis RA Pitera RT Payne SN Korkos DP Clipson L Walsh CM Miller D Carchman EH Burkard ME Lemmon KK Matkowskyj KA Newton MA Ong IM Bassetti MF Kimple RJ Skala MC Deming DA Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Clin Cancer Res . 2019 Sep 1;25(17):5376-5387
[PubMed ID: 31175091]
Denu RA Sass MM Johnson JM Potts GK Choudhary A Coon JJ Burkard ME Polo-like kinase 4 maintains centriolar satellite integrity by phosphorylation of centrosomal protein 131 (CEP131). J Biol Chem . 2019 Apr 19;294(16):6531-6549
[PubMed ID: 30804208]
Stefely JA Theisen E Hanewall C Scholl L Burkard ME Huttenlocher A Yu JJ A physician-scientist preceptorship in clinical and translational research enhances training and mentorship. BMC Med Educ . 2019 Mar 27;19(1):89
[PubMed ID: 30917818]
Tevaarwerk AJ Hocking WG Buhr KA Gribble M Seaborne LA Wisinski KB Burkard ME Yen T Wiegmann DA Sesto ME A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment. Cancer . 2019 Mar 15;125(6):1000-1007
[PubMed ID: 30690714]
Rocque GB Kandhare PG Williams CP Nakhmani A Azuero A Burkard ME Forero A Bhatia S Kenzik KM Visualization of Sequential Treatments in Metastatic Breast Cancer. JCO Clin Cancer Inform . 2019 Mar;3:1-8
[PubMed ID: 30840488]
Fricke SL Payne SN Favreau PF Kratz JD Pasch CA Foley TM Yueh AE Van De Hey DR Depke MG Korkos DP Sha GC DeStefanis RA Clipson L Burkard ME Lemmon KK Parsons BM Kenny PA Matkowskyj KA Newton MA Skala MC Deming DA MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers. Mol Cancer Ther . 2019 Feb;18(2):346-355
[PubMed ID: 30425131]
Burkard ME Golden RN Shared Knowledge in Precision Cancer Care. WMJ . 2018 Oct;117(4):178-179
[PubMed ID: 30407771]
Jin N Burkard ME MACROD2, an Original Cause of CIN? Cancer Discov . 2018 Aug;8(8):921-923
[PubMed ID: 30076143]
Kratz J Burkard M O'Meara T Pusztai L Veitch Z Bedard PL Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. Am Soc Clin Oncol Educ Book . 2018 May 23;38:56-64
[PubMed ID: 30231387]
Denu RA Shabbir M Nihal M Singh CK Longley BJ Burkard ME Ahmad N Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res . 2018 Mar;16(3):517-527
[PubMed ID: 29330283]
Shah RA Bennett DD Burkard ME Photosensitive lichenoid skin reaction to capecitabine. BMC Cancer . 2017 Dec 19;17(1):866
[PubMed ID: 29258457]
Ma CX Suman V Goetz MP Northfelt D Burkard ME Ademuyiwa F Naughton M Margenthaler J Aft R Gray R Tevaarwerk A Wilke L Haddad T Moynihan T Loprinzi C Hieken T Barnell EK Skidmore ZL Feng YY Krysiak K Hoog J Guo Z Nehring L Wisinski KB Mardis E Hagemann IS Vij K Sanati S Al-Kateb H Griffith OL Griffith M Doyle L Erlichman C Ellis MJ A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res . 2017 Nov 15;23(22):6823-6832
[PubMed ID: 28874413]
Wu CG Chen H Guo F Yadav VK Mcilwain SJ Rowse M Choudhary A Lin Z Li Y Gu T Zheng A Xu Q Lee W Resch E Johnson B Day J Ge Y Ong IM Burkard ME Ivarsson Y Xing Y PP2A-B' holoenzyme substrate recognition, regulation and role in cytokinesis. Cell Discov . 2017;3:17027
[PubMed ID: 28884018]
Denu RA Burkard ME Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. Clin Breast Cancer . 2017 Jun;17(3):e151-e153
[PubMed ID: 28139434]
Tevaarwerk AJ Hocking WG Zeal JL Gribble M Seaborne L Buhr KA Wisinski KB Burkard ME Wiegmann DA Sesto ME Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. J Oncol Pract . 2017 May;13(5):e486-e495
[PubMed ID: 28221896]
Burkard ME Deming DA Lauring J Using cancer genomics to guide clinical decisions. Cancer . 2017 Apr 15;123(8):1288-1291
[PubMed ID: 28253425]
Burkard ME Weaver BA Tuning Chromosomal Instability to Optimize Tumor Fitness. Cancer Discov . 2017 Feb;7(2):134-136
[PubMed ID: 28167614]
Rampurwala M Wisinski KB Burkard ME Ehsani S O'Regan RM Carmichael L Kim K Kolesar J Tevaarwerk AJ Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs . 2017 Feb;35(1):87-94
[PubMed ID: 27826831]